Addressing challenges in AAV manufacturing scale-up for cost-effective gene therapies
Year: 2025
Type: article
Abstract: “Currently approved therapies have a very high price, and much of that is driven by the expensive raw materials and costly manufacturing processes.”Jokūbas Leikauskas, Editor, BioInsights, speaks to Andrew D Tustian, Executive Director, Preclinical Manufacturing and Process Development, Regeneron, about the advancements in AAV process development from preclinical to commercial stages, addressing challenges in scaling, automation, and cost reduction, while prioritizing the delivery of innovative gene therapies to patients.
Source: Cell and Gene Therapy Insights
Author: Andrew D Tustian
Institution: Regeneron (United States)
Language: English
Subfield: Genetics
Domain: Life Sciences
Open Access status: hybrid
OpenAlex ID: W4417331185
FWCI:
Cites:
Cited by:
Related to: